Promis Neurosciences Inc <PMN.O>: Chardan Capital Markets initiates coverage with Buy rating; price target $20
PMN•Related News
NAB sees Australia consumption growth slowing to 1.4% in 2026-27
EWA•
South Korea's Naver jumps 10% on Nvidia's $1 billion investment plan
NVDA•
USCB Financial Holdings Inc <USCB.O>: Piper Sandler raises target price to $27 from $24
USCB•
Canadian National Railway Co: TD Cowen Raises Target Price to C$205 From C$191
CNI•
Phillips 66 Reports Process Upset at Sweeny, Texas plant
PSX•